Di Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Di Zhou has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Bing Chen
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
3 shared publicationsJian Ouyang
Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
2 shared publicationsPeipei Xu
Nanjing Drum Tower Hospital, Nanjing, China
2 shared publicationsYueyi Xu
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
2 shared publications- Biao Zhao
Nanjing Drum Tower Hospital, Nanjing, China
1 shared publication Chao Zhang
Department of Research and Development, Sysdiagno (Nanjing) Biotech Co. Ltd, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by American Society of Hematology in Blood Advances
The total serum N-glycome landscape of hematological malignancies
A holistic and dynamic view of the glycomic landscape in hematological malignancies (HMs) remains poorly characterized, hindering clinical the application of glycomics in HMs. We launched a large-scale analysis of multicenter cohorts, combining retrospective (n=1,370) and prospective longitudinal (n=130) data across major HM types. We defined distinct total serum N‑glycome (TSNG) profiles for multiple myeloma, lymphoma, and acute leukemia at diagnosis, revealing shared and disease-specific signatures that support their diagnostic and subtyping potential. TSNG features changed with disease status. Key glycans decreased significantly upon complete remission and increased again at relapse. Receiver operating characteristic curve analyses demonstrated that TSNG could distinguish disease states, supporting its utility for assessing treatment response. We systematically mapped the TSNG landscape of HMs, established its clinical relevance across diagnosis, subtyping, and treatment monitoring, providing a framework for advancing the glycomics-based understanding and management of these malignancies.
- 6 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessThe total serum N-glycome landscape of hematological malignancies
A holistic and dynamic view of the glycomic landscape in hematological malignancies (HMs) remains poorly characterized, hindering clinical the application of glycomics in HMs. We launched a large-scale analysis of multicenter cohorts, combining retrospective (n=1,370) and prospective longitudinal (n=130) data across major HM types. We defined distinct total serum N‑glycome (TSNG) profiles for multiple myeloma, lymphoma, and acute leukemia at diagnosis, revealing shared and disease-specific signatures that support their diagnostic and subtyping potential. TSNG features changed with disease status. Key glycans decreased significantly upon complete remission and increased again at relapse. Receiver operating characteristic curve analyses demonstrated that TSNG could distinguish disease states, supporting its utility for assessing treatment response. We systematically mapped the TSNG landscape of HMs, established its clinical relevance across diagnosis, subtyping, and treatment monitoring, providing a framework for advancing the glycomics-based understanding and management of these malignancies.
- Open Access
- 13 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (3) , 361-375
TMEM187 is a novel modulator in the regulation of erythropoiesis
Erythropoiesis, the process of red blood cell production, is highly dependent on iron uptake via transferrin and its receptor, transferrin receptor 1 (TfR1), but the mechanisms governing the proper recycling of TfR1 in relation to cellular iron demands remain elusive. Here, we identify human TMEM187, a Golgi transmembrane protein of unknown function, as a novel negative regulator of erythropoiesis. Lack of TMEM187 in a cell model initiates erythropoiesis without the normal induction protocol and accelerates iron uptake. Following the induction protocol, TMEM187 ablation leads to premature erythroid maturation, resulting in early phosphatidylserine ectopia and cell membrane fragility, hallmarks of cellular senescence that renders the cells susceptible to macrophage recognition and phagocytosis. In zebrafish embryos, tmem187 deletion leads to enhanced early erythropoiesis, although the phenotype is later compensated, whereas hematopoietic stem-cell expression of human TMEM187 in mice, which lack endogenously a homologous gene, resulted in compromised erythropoiesis and moderate anemia. Mechanistically, we demonstrate that TMEM187 interacts with RAB11 to restrain endosomal recycling, interfering with RAB11-GRAB association that activates RAB11. Consequently, TMEM187 modulates TfR1 recycling to the cell membrane to fine-tune iron uptake efficiency for erythropoiesis. Our findings reveal a novel modulatory pathway in which TMEM187 plays a crucial role in regulating erythroid differentiation, maturation, and senescence, providing a previously unexplored perspective of TMEM187's physiological function.
- 13 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (3) , 361-375
Open AccessTMEM187 is a novel modulator in the regulation of erythropoiesis
Erythropoiesis, the process of red blood cell production, is highly dependent on iron uptake via transferrin and its receptor, transferrin receptor 1 (TfR1), but the mechanisms governing the proper recycling of TfR1 in relation to cellular iron demands remain elusive. Here, we identify human TMEM187, a Golgi transmembrane protein of unknown function, as a novel negative regulator of erythropoiesis. Lack of TMEM187 in a cell model initiates erythropoiesis without the normal induction protocol and accelerates iron uptake. Following the induction protocol, TMEM187 ablation leads to premature erythroid maturation, resulting in early phosphatidylserine ectopia and cell membrane fragility, hallmarks of cellular senescence that renders the cells susceptible to macrophage recognition and phagocytosis. In zebrafish embryos, tmem187 deletion leads to enhanced early erythropoiesis, although the phenotype is later compensated, whereas hematopoietic stem-cell expression of human TMEM187 in mice, which lack endogenously a homologous gene, resulted in compromised erythropoiesis and moderate anemia. Mechanistically, we demonstrate that TMEM187 interacts with RAB11 to restrain endosomal recycling, interfering with RAB11-GRAB association that activates RAB11. Consequently, TMEM187 modulates TfR1 recycling to the cell membrane to fine-tune iron uptake efficiency for erythropoiesis. Our findings reveal a novel modulatory pathway in which TMEM187 plays a crucial role in regulating erythroid differentiation, maturation, and senescence, providing a previously unexplored perspective of TMEM187's physiological function.
- Open Access
- 6 June 2024
- Published by Wiley
Hematological Characteristics in Risk Classification of SARS-CoV2 Delta Variant
Background COVID-19 is an ongoing pandemic posing a big threat to public health and economy. Novel variants are constantly emerging with different transmissibility and pathogenicity. This study aimed to explore the hematological characteristics of COVID-19 delta variant during the outbreak in July 2021, Nanjing. Methods This study retrospectively analyzed demographic and clinical parameters of 80 patients diagnosed with COVID-19 delta variant infection. Patients were classified into mild, moderate and severe/critical group according to the guideline. Characteristics of each group were compared. Results The percentage of elderly and patients with comorbidities was significantly higher in the severe/critical group. Vaccination rate was significantly lower in this group. Decreased lymphocyte number, especially CD4+ and CD8+ T cells, elevated fibrinogen, CRP, PCT and IL-6 were associated with disease severity (P<0.05). Severe or critical cases tended to have higher viral load shown by lower CT values of ORF1ab and N gene (P=0.08, P=0.06) and lower specific IgG antibody level (P=0.15) but it did not reach statistical significance. Conclusions Increasing vaccination rate in the elderly and population with comorbidities might improve the prognosis of COVID-19 delta variant. Mechanism study of immune evasion of COVID-19 and methods to booster our immune system was urgently needed.
- 6 June 2024
- Published by Wiley
Open AccessHematological Characteristics in Risk Classification of SARS-CoV2 Delta Variant
Background COVID-19 is an ongoing pandemic posing a big threat to public health and economy. Novel variants are constantly emerging with different transmissibility and pathogenicity. This study aimed to explore the hematological characteristics of COVID-19 delta variant during the outbreak in July 2021, Nanjing. Methods This study retrospectively analyzed demographic and clinical parameters of 80 patients diagnosed with COVID-19 delta variant infection. Patients were classified into mild, moderate and severe/critical group according to the guideline. Characteristics of each group were compared. Results The percentage of elderly and patients with comorbidities was significantly higher in the severe/critical group. Vaccination rate was significantly lower in this group. Decreased lymphocyte number, especially CD4+ and CD8+ T cells, elevated fibrinogen, CRP, PCT and IL-6 were associated with disease severity (P<0.05). Severe or critical cases tended to have higher viral load shown by lower CT values of ORF1ab and N gene (P=0.08, P=0.06) and lower specific IgG antibody level (P=0.15) but it did not reach statistical significance. Conclusions Increasing vaccination rate in the elderly and population with comorbidities might improve the prognosis of COVID-19 delta variant. Mechanism study of immune evasion of COVID-19 and methods to booster our immune system was urgently needed.
- 31 October 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (1) , 16-22
Correlation of miR‐181a and three HOXA genes as useful biomarkers in acute myeloid leukemia
Introduction: MiR‐181a is a small, noncoding RNA that plays important roles in the pathogenesis and prognosis of acute myeloid leukemia (AML). A group of HOXA genes, including HOXA7, HOXA9, and HOXA11, has been established as an independent predictor for AML prognosis. In this study, we aimed to investigate the association between miR‐181a and HOXA7, HOXA9, and HOXA11 and explore their roles in predicting prognosis in AML.Patients and Methods: Bone marrow samples of 46 untreated AML patients and 9 healthy donors were collected. Mononuclear cells were purified using density‐gradient centrifugation in Ficoll, and quantitative real‐time PCR was used to detect miR‐181a and HOXA gene expression level.Results: HOXA7, HOXA9, and HOXA11 were negatively correlated with miR‐181a, and their expression levels varied among AML subtypes, karyotypes, and risk status. Higher miR‐181a and lower HOXA gene expressions were significantly associated with lower risk status and better response to chemotherapy.Conclusion: In our study, we found miR‐181a expression was negatively correlated with three HOXA genes and they were associated with AML risk status and prognosis in granulocytic AML. It further supported that miR‐181a could be a useful marker for AML prognosis and possibly worked by regulating HOXA gene clusters.
- 31 October 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (1) , 16-22
Correlation of miR‐181a and three HOXA genes as useful biomarkers in acute myeloid leukemia
Introduction: MiR‐181a is a small, noncoding RNA that plays important roles in the pathogenesis and prognosis of acute myeloid leukemia (AML). A group of HOXA genes, including HOXA7, HOXA9, and HOXA11, has been established as an independent predictor for AML prognosis. In this study, we aimed to investigate the association between miR‐181a and HOXA7, HOXA9, and HOXA11 and explore their roles in predicting prognosis in AML.Patients and Methods: Bone marrow samples of 46 untreated AML patients and 9 healthy donors were collected. Mononuclear cells were purified using density‐gradient centrifugation in Ficoll, and quantitative real‐time PCR was used to detect miR‐181a and HOXA gene expression level.Results: HOXA7, HOXA9, and HOXA11 were negatively correlated with miR‐181a, and their expression levels varied among AML subtypes, karyotypes, and risk status. Higher miR‐181a and lower HOXA gene expressions were significantly associated with lower risk status and better response to chemotherapy.Conclusion: In our study, we found miR‐181a expression was negatively correlated with three HOXA genes and they were associated with AML risk status and prognosis in granulocytic AML. It further supported that miR‐181a could be a useful marker for AML prognosis and possibly worked by regulating HOXA gene clusters.
- Open Access
- 23 April 2019
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 17 (6) , 4617-4627
Identification of potential therapeutic target genes in mouse mesangial cells associated with diabetic nephropathy using bioinformatics analysis
The aim of the present study was to identify genes under the effect of transforming growth factor‑β (TGF‑β1), high glucose (HG) and glucosamine (GlcN) in MES‑13 mesangial cells and elucidate the molecular mechanisms of diabetic nephropathy (DN). The gene expression datasets GSE2557 and GSE2558 were downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were independently screened using the GEO2R online tool. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the Database for Annotation, Visualization, and Integrated Discovery. The protein‑protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes and Cytoscape software. The hub genes were identified by the NetworkAnalyzer plugin. Overlapping genes were subjected to molecular docking analysis using SystemsDock. A total of 202 upregulated and 158 downregulated DEGs from the HG‑treated groups, 138 upregulated and 103 downregulated DEGs from the GlcN‑treated groups, and 81 upregulated and 44 downregulated DEGs from the TGF‑β1‑treated groups were identified. The majority of the DEGs were independently enriched in ‘nucleosome assembly’, ‘chromatin silencing’ and ‘xenobiotic glucuronidation’. In addition, KEGG pathways were significantly enriched in ‘systemic lupus erythematosus’, ‘protein processing in endoplasmic reticulum’ and ‘aldarate metabolism pathway’, and ‘TNF signaling pathway’ intersected in the TGF‑β1‑treated and HG‑treated groups. In total, eight hub genes, Jun, prostaglandin‑endoperoxide synthase 2 (Ptgs2), fibronectin 1 (Fn1), cyclin‑dependent kinase (Cdk)2, Fos, heat shock protein family A (Hsp70) member 5 (Hspa5), Hsp90b1 and homo sapiens hypoxia upregulated 1 (Hyou1), and three overlapping genes, Ras homolog gene family, member B (RHOB), complement factor H (CFH) and Krüppel‑like factor 15 (KLF15), were selected. Valsartan with RHOB, and fosinopril with CFH and KLF15 had preferential binding activity. In conclusion, Jun, Ptgs2, Fn1, Cdk2, Fos, Hspa5, Hsp90b1, Hyou1, RHOB, CFH and KLF15 may be potential therapeutic targets for mesangial cells associated with DN, which may provide insight into DN treatment strategies.
- 23 April 2019
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 17 (6) , 4617-4627
Open AccessIdentification of potential therapeutic target genes in mouse mesangial cells associated with diabetic nephropathy using bioinformatics analysis
The aim of the present study was to identify genes under the effect of transforming growth factor‑β (TGF‑β1), high glucose (HG) and glucosamine (GlcN) in MES‑13 mesangial cells and elucidate the molecular mechanisms of diabetic nephropathy (DN). The gene expression datasets GSE2557 and GSE2558 were downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were independently screened using the GEO2R online tool. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the Database for Annotation, Visualization, and Integrated Discovery. The protein‑protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes and Cytoscape software. The hub genes were identified by the NetworkAnalyzer plugin. Overlapping genes were subjected to molecular docking analysis using SystemsDock. A total of 202 upregulated and 158 downregulated DEGs from the HG‑treated groups, 138 upregulated and 103 downregulated DEGs from the GlcN‑treated groups, and 81 upregulated and 44 downregulated DEGs from the TGF‑β1‑treated groups were identified. The majority of the DEGs were independently enriched in ‘nucleosome assembly’, ‘chromatin silencing’ and ‘xenobiotic glucuronidation’. In addition, KEGG pathways were significantly enriched in ‘systemic lupus erythematosus’, ‘protein processing in endoplasmic reticulum’ and ‘aldarate metabolism pathway’, and ‘TNF signaling pathway’ intersected in the TGF‑β1‑treated and HG‑treated groups. In total, eight hub genes, Jun, prostaglandin‑endoperoxide synthase 2 (Ptgs2), fibronectin 1 (Fn1), cyclin‑dependent kinase (Cdk)2, Fos, heat shock protein family A (Hsp70) member 5 (Hspa5), Hsp90b1 and homo sapiens hypoxia upregulated 1 (Hyou1), and three overlapping genes, Ras homolog gene family, member B (RHOB), complement factor H (CFH) and Krüppel‑like factor 15 (KLF15), were selected. Valsartan with RHOB, and fosinopril with CFH and KLF15 had preferential binding activity. In conclusion, Jun, Ptgs2, Fn1, Cdk2, Fos, Hspa5, Hsp90b1, Hyou1, RHOB, CFH and KLF15 may be potential therapeutic targets for mesangial cells associated with DN, which may provide insight into DN treatment strategies.